未登录

J

Jolien J. M. Freriksen

department of pharmacy

H指数:12

被引数:417

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Physiologically Based Pharmacokinetic Modeling-Based Evaluation of Current Carbamazepine and Valproic Acid Dosing Guidelines for Pediatric Epilepsy Treatment

基于生理药代动力学模型对当前卡马西平和丙戊酸儿科癫痫治疗剂量指南的评估

Pediatric Drugs

IF3.3

2025-07-020

OA

Model-informed repurposing of eliglustat for treatment and prophylaxis of Shiga toxin-producing Escherichia coli hemolytic-uremic syndrome (STEC-HUS) in children

基于模型的eliglustat重定位用于儿童产志贺毒素大肠杆菌溶血尿毒综合征(STEC-HUS)的治疗和预防

PEDIATRIC NEPHROLOGY

IF2.6

2025-02-030

OA

Physiologically-Based Pharmacokinetic Modeling for Drug Dosing in Pediatric Patients: A Tutorial for a Pragmatic Approach in Clinical Care

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2023-09-0510

OAAI

Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling

IF5.5

2023-05-062

OAAI

Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population

PEDIATRIC DRUGS

IF3.3

2022-10-069

OAAI

Off-Label, but on-Evidence? A Review of the Level of Evidence for Pediatric Pharmacotherapy

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2022-09-2529

OAAI

Placental transfer and vascular effects of pharmaceutical drugs in the human placenta ex vivo: A review

IF2.5

2022-05-016

OAAI

Best Evidence-Based Dosing Recommendations for Dexmedetomidine for Premedication and Procedural Sedation in Pediatrics: Outcome of a Risk-Benefit Analysis By the Dutch Pediatric Formulary

PEDIATRIC DRUGS

IF3.3

2022-03-2811

OAAI

Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

IF8.4

2020-12-012

PREAI

The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus

CLINICAL INFECTIOUS DISEASES

IF7.3

2020-02-2633

PREAI

Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2020-01-2433

OAAI

Review article: Direct-acting antivirals for the treatment of HCV during pregnancy and lactation: implications for maternal dosing, foetal exposure, and safety for mother and child

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2019-08-2536

OAAI

Placental disposition of the immunosuppressive drug tacrolimus in renal transplant recipients and in ex vivo perfused placental tissue

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

IF4.7

2018-07-0119

OAAI